Progestogens in obstetrics: Which type and route????
-
Upload
aboubakr-elnashar -
Category
Health & Medicine
-
view
1.064 -
download
0
Transcript of Progestogens in obstetrics: Which type and route????
Progestogens in obstetrics: Which type and route????
Aboubakr Elnashar
Benha university, Egypt
Aboubakr Elnashar
CONTENTS
1. Progestagen used during pregnancy
2. Absorption
3. Vaginal progestagen and 17 hp
4. Uses of progestagens in obstetrics
Conclusion
4 Aboubakr Elnashar
I. Progestagen used during pregnancy
Progestogen Compound with progesterone-like action Produces progestational changes in an oestrogen-primed endometrium. Transform a proliferative into a secretory endometrium to support pregnancy.
Natural
Synthetic.
Aboubakr Elnashar
Natural progestagens
Synthesized from: plant sources: soybeans and Mexican yam roots occasionally from: animal ovaries. The hormone is not available from any natural source without extraction and synthesis
Chemically and structurally identical to human
progesterone: “bioidentical” or “natural”.
Forms:
1. Oral
2. Intravaginal
3. Injectable
Aboubakr Elnashar
Synthetic Progestogens= Progestins
synthetically produced and differs in structure from
progesterone.
Progesterone derivatives:
17α-oH progesterone caproate
Stereoisomers of progesterone
Dydrogesterone
Aboubakr Elnashar
II. ABSORBTION
Transvaginal Progesterone.
:uterine effects with minimal systemic side effects (Fanchin et al, 1997).
One hour after application Four hours after application
Endometrial Diffusion: Targeted delivery: Micronised Vaginal Progesterone
Progressive diffusion of progesterone from the cervix to the fundus of the uterus
(Bulletti et al. Hum Reprod. 1997)
Aboubakr Elnashar
Vaginal progesterone increases endometrial tissue levels
(Fert.Steril, 2012)
Aboubakr Elnashar
IM progesterone is associated with the highest
serum levels (Fert.Steril, 2012)
Aboubakr Elnashar
III. DIFFERENCE BETWEEN NATURAL
PROGESTAGEN AND 17HP
Aboubakr Elnashar
Short cervix
Vaginal progesterone reduced the incidence of
PTL (Fonseca et al, 2007; Hassan et al, 2011)
17a OH P C did not. (Grobman et al, 2012)
Prior PTL
17a OH P C reduced the incidence of PTL (Meis et al, 2003)
Vaginal progesterone did not. (O’Brien et al, 2007)
Aboubakr Elnashar
IV. USES IN OBSTETRICS
1.Threatened miscarriages
2.Recurrent miscarriages
3.Prevention of PTL in singleton pregnancy
4.Prevention of PTL in twin pregnancy
Aboubakr Elnashar
1. THREATENED MISCARRIAGES
Cochrane S R. 2011:
4 studies (421)
Pandian
2009
El-Zibdeh
2009
Palagiano
2004
Gerhard
1987
(n=191) (n=146) (n=50) (n=64)
initial 40 mg
oral
dydrogesterone
followed by 10
mg twice/d
continued until
16 w
90 mg
progesterone
(Crinone
8%) vaginal
sups once
daily
for 5d
oral dydrogesterone
10 mg twice/d
continued for
1 w after
bleeding
stopped
25mg;
progesterone;
twice/d vaginal
sups
continued for
14 d after
bleeding stopped
Aboubakr Elnashar
Progestogens is effective in the tt of threatened
miscarriage
Reduced the risk of miscarriage by 47% (with a
confidence interval consistent with a risk reduction of 21% to 65%).
Significant reduction in the mean pain score (Palagiano 2004)
Vaginal progesterone was not statistically effective
in reducing miscarriage
Aboubakr Elnashar
No statistically significant difference in between the women who received
congenital abnormalities, PIH APH progestogens and those who did not.
Limitation of MA:
1. poor methodological quality of studies
2. small number of the participants
Aboubakr Elnashar
Carp, 2012, MA
11% absolute reduction in the miscarriage rate. significant reduction of 47% in the odds for miscarriage when dydrogesterone is compared to standard care
Many miscarriages are caused by genetic
abnormalities in the conceptus. It is unlikely that
progestins could prevent a miscarriage of this
etiology.
control Dydrogesterone
325 335 Patients
24% 13% Miscarriage rate
Aboubakr Elnashar
Dante et al, 2013
No evidence to support the routine use of
progesterone vaginal supp for the treatment of
threatened miscarriage.
Aboubakr Elnashar
Yassaee et al, 2014
Rate of abortion was reduced in women treated
with 400 mg vaginal progesterone suppository (Cyclogest) each day until their bleeding stopped in less than one week.
However, the difference was not statistically
significant.
Aboubakr Elnashar
2. RECURRENT MISCARRIAGES
Mechanism:
Immmunomodulatory actions
Decreasing proinflammatory
Increasing anti-inflammatory cytokines in early
pregnancy [Choi et al, 2000].
Duration:
Start: 3 days after the LH surge {not to inhibit
ovulation}
Continue: until 10 w
{placental progesterone production fully functional}
Aboubakr Elnashar
Cochrane Database S R. 2013
4 trials, 225 women
El-Zibdeh
2005
Goldzieher 1964 Le Vine
1964
Swyer
1953
180 54 56 113
10 mg bid oral
Dydrogesterone,
5000 IU IM
hCG/4d
Duration: 12th w
10 mg/d oral
Dydrogesterone,
Duration: not
stated.
500 mg/w
IM
17 oh PC
Duration:
until 36 w
6 x 25 mg
progesterone
pellets
Duration: unclear.
Aboubakr Elnashar
3 or more consecutive miscarriages
Progestogen tt:
significant decrease in miscarriage rate compared
to placebo or no tt (Peto OR 0.39; 95% CI 0.21 to 0.72).
2 prior miscarriages.
a trend but not a significant reduction in miscarriage
rates (Peto OR 0.68; 95% CI 0.43 to 1.07).
Limitations of MA:
these 4 trials were of poorer methodological quality.
Aboubakr Elnashar
Carp et al, 2015, SR and MA
509 women
13% absolute reduction in the miscarriage rate significant reduction of 29% in the odds for miscarriage when dydrogesterone is compared to standard care
Control Dydrogesterone
23.5% 10.5% Miscarriage rate
Aboubakr Elnashar
Aboubakr Elnashar
Coomarasamy et al, 2015: NEMJ
PROMISE STUDY: 836 patients
•multicenter, double-blind, placebo-controlled, randomized trial Vaginal suppositories: 400 mg micronized
progesterone in 1st T did not result in a significantly
higher LBR among women with a history of un RM.
3. PREVENTION OF PTL IN SINGLETON
PREGNANCY
Mechanisms of action 1. Stimulate transcription of ZEB1 and ZEB2: inhibit connexin
43 (gap-junction protein that helps synchronize contractile activity) and oxytocin-receptor gene
2. Decrease prostaglandin synthesis, infection-mediated cytokine production (antiinflammatory effects) by fetal membranes/placenta
3. Changes in PR-A and PR-B expression (decreased PR-A/PR-B ratio keeps uterus quiescent)
4. Membrane-bound PR in myometrium
Aboubakr Elnashar
Maternal –Fetal medicine Society, 2012
Aboubakr Elnashar
Aboubakr Elnashar
Cochrane Syst Rev.2013
Progesterone vs placebo for women with a
past history of PTB
statistically significant reduction in the risk of
Perinatal mortality PTB less than 34 w PTB less than 37 w No differential effects in terms of:
Route of administration
time of commencing therapy dose of progesterone
Aboubakr Elnashar
Progesterone vs placebo for women with a
short cervix identified on US
statistically significant reduction in the risk of
PTB less than 34 w PTB at less than 28 w It was not possible to assess the effect of
Route of administration
gestational age at commencing therapy, or total cumulative dose of medication.
Aboubakr Elnashar
NICE, 2015
Offer prophylactic vaginal progesterone to women
with
no history of PTB or mid-trimester loss
in whom
TVS has been carried out between 16+0 and
24+0 w that reveals a cervical length of less than
25 mm.
Aboubakr Elnashar
Norman et al, 2016: Lancet.
OPPTIMUM study
1,228 women
Double blind, RCT, placebo trial
vaginal progesterone, 200 mg daily taken from 22-
24 to 34 w
women at risk of PTB
previous spontaneous birth at ≤34 w
cervical length ≤25 mm
Vaginal progesterone
not associated with reduced risk of PTB or
composite neonatal adverse outcomes no longterm benefit or harm on outcomes in children at 2 y of age.
Aboubakr Elnashar
4. PREVENTION OF PTL IN TWIN PREGNANCY
Maternal –Fetal medicine Society, 2012
No evidence of effectiveness
Cochrane Syst Rev.2013
Progesterone vs placebo for women with a
multiple pregnancy
no statistically significant differences
Aboubakr Elnashar
Schuit et al, 2014, MA
13 trials included 3768 women
Neither 17Pc (250 mg/w) nor
vaginal progesterone **
reduced the incidence of PTL
**Pessary: 200-400 mg Gel: 90 mg Sups: 100 -400 mg Caps: 200 mg
Aboubakr Elnashar
In a subgroup of women with a cervical length of
≤25 mm:
vaginal progesterone reduced PTL when cervical length was measured at randomisation (15/56 vs 22/60; RR 0.57; 95% CI 0.47–0.70) or
before 24 w of gestation (14/52 vs 21/56; RR 0.56;95% CI
0.42–0.75).
Aboubakr Elnashar
Brubaker et al, 2015
vaginal progesterone therapy in twin pregnancies
with a CL ≤2.5 cm: an increased risk of PTB
Brizot et al, 2015
In nonselected twin pregnancies,
vaginal progesterone administration:
No prevent and does not reduce neonatal
morbidity and death.
Aboubakr Elnashar
CONCLUSION
1. T M and RM: Oral
2. PTL in Singleton:
Short cx: vaginal (NICE, 2015)
Previous PTL: IM
4. PTL in Twin:
Short cx: vaginal (Schuit et al, 2014, MA)
Aboubakr Elnashar
263 lectures
1. My scientific
page on face
book: 3604
members
2. Slide share: 1228
followers
Aboubakr Elnashar